当前位置: X-MOL 学术Interdiscip. Cardiovasc. Thorac. Surg. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Successful use of bio plugs for delayed bronchial closure after pneumonectomy in experimental settings
Interdisciplinary CardioVascular and Thoracic Surgery ( IF 1.6 ) Pub Date : 2021-10-18 , DOI: 10.1093/icvts/ivab306
Masaaki Moriyama 1, 2 , Keitaro Matsumoto 1, 2 , Daisuke Taniguchi 1, 2 , Ryusuke Machino 1, 2 , Tomoshi Tsuchiya 1 , Koichi Nakayama 3 , Takeshi Nagayasu 1, 2
Affiliation  

OBJECTIVES Cell therapies, such as stem cell suspension injection, are used to treat bronchopleural fistula. Although it is safe and effective, injected cells cannot remain within the bronchioles of the fistula due to cell leakage into the thoracic cavity. Here, we inserted a ‘bio plug’ into the fistula, produced using cells and a bio-3D printer, to examine the effectiveness of bio plugs for the closure of bronchopleural fistulas, the optimal cell source and the closure mechanism. METHODS Bio plugs were made with mesenchymal stem (stromal) cells derived from bone marrow (MSCBM), fibroblasts and rat lung micro-vessel endothelial cells using a bio-3D printer with different cell mixing ratios. Six groups, according to the presence or absence and the type of bio plugs, were compared. The plugs were inserted into the bronchi of F344 rats. The obstruction ratio and histological and immunohistochemical findings were evaluated. RESULTS MSCBM+ rat lung micro-vessel endothelial cell group exhibited a higher obstruction ratio among all groups excluding the MSCBM group (P = 0.039). This group had fibrosis and CD31-positive cells and fewer CD68-positive cells than MSCBM and MSCBM+ fibroblast groups. CONCLUSIONS Bio plugs with mixed cells, including stem cells, contribute to bronchial closure in the current experimental setting. Endothelial cells effectively maintain the structure in this model. Although bronchial closure for bronchopleural fistula could not be described as clinical conditions were not reproduced, we collected essential data on bronchial closure; however, further experiments are warranted.

中文翻译:

在实验环境中成功使用生物栓在全肺切除术后延迟支气管关闭

目标细胞疗法,例如干细胞悬浮注射液,用于治疗支气管胸膜瘘。尽管它安全有效,但由于细胞泄漏到胸腔中,注射的细胞不能留在瘘管的细支气管内。在这里,我们将使用细胞和生物 3D 打印机生产的“生物塞”插入瘘管,以检查生物塞在关闭支气管胸膜瘘、最佳细胞来源和关闭机制方面的有效性。方法 使用不同细胞混合比的生物 3D 打印机,使用源自骨髓 (MSCBM)、成纤维细胞和大鼠肺微血管内皮细胞的间充质干(基质)细胞制作生物塞。根据生物塞的存在或不存在和类型,对六组进行了比较。将塞子插入 F344 大鼠的支气管。评估阻塞率和组织学和免疫组化结果。结果MSCBM+大鼠肺微血管内皮细胞组在除MSCBM组外的所有组中均表现出较高的阻塞率(P=0.039)。与 MSCBM 和 MSCBM+ 成纤维细胞组相比,该组有纤维化和 CD31 阳性细胞和更少的 CD68 阳性细胞。结论 具有混合细胞(包括干细胞)的生物塞有助于当前实验环境中的支气管闭合。内皮细胞有效地维持该模型中的结构。虽然支气管胸膜瘘的支气管闭合不能被描述为临床情况未重现,但我们收集了支气管闭合的基本数据;但是,还需要进一步的实验。结果MSCBM+大鼠肺微血管内皮细胞组在除MSCBM组外的所有组中均表现出较高的阻塞率(P=0.039)。与 MSCBM 和 MSCBM+ 成纤维细胞组相比,该组有纤维化和 CD31 阳性细胞和更少的 CD68 阳性细胞。结论 具有混合细胞(包括干细胞)的生物塞有助于当前实验环境中的支气管闭合。内皮细胞有效地维持该模型中的结构。虽然支气管胸膜瘘的支气管闭合不能被描述为临床情况未重现,但我们收集了支气管闭合的基本数据;但是,还需要进一步的实验。结果MSCBM+大鼠肺微血管内皮细胞组在除MSCBM组外的所有组中均表现出较高的阻塞率(P=0.039)。与 MSCBM 和 MSCBM+ 成纤维细胞组相比,该组有纤维化和 CD31 阳性细胞和更少的 CD68 阳性细胞。结论 具有混合细胞(包括干细胞)的生物塞有助于当前实验环境中的支气管闭合。内皮细胞有效地维持该模型中的结构。虽然支气管胸膜瘘的支气管闭合不能被描述为临床情况未重现,但我们收集了支气管闭合的基本数据;但是,还需要进一步的实验。与 MSCBM 和 MSCBM+ 成纤维细胞组相比,该组有纤维化和 CD31 阳性细胞和更少的 CD68 阳性细胞。结论 具有混合细胞(包括干细胞)的生物塞有助于当前实验环境中的支气管闭合。内皮细胞有效地维持该模型中的结构。虽然支气管胸膜瘘的支气管闭合不能被描述为临床情况未重现,但我们收集了支气管闭合的基本数据;但是,还需要进一步的实验。与 MSCBM 和 MSCBM+ 成纤维细胞组相比,该组有纤维化和 CD31 阳性细胞和更少的 CD68 阳性细胞。结论 具有混合细胞(包括干细胞)的生物塞有助于当前实验环境中的支气管闭合。内皮细胞有效地维持该模型中的结构。虽然支气管胸膜瘘的支气管闭合不能被描述为临床情况未重现,但我们收集了支气管闭合的基本数据;但是,还需要进一步的实验。虽然支气管胸膜瘘的支气管闭合不能被描述为临床情况未重现,但我们收集了支气管闭合的基本数据;但是,还需要进一步的实验。虽然支气管胸膜瘘的支气管闭合不能被描述为临床情况未重现,但我们收集了支气管闭合的基本数据;但是,还需要进一步的实验。
更新日期:2021-10-18
down
wechat
bug